Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11635954 | 0.89 | TSHR (0.50) | TSHRKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL839062 | 0.87 | TSHR (0.48) | TSHRKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL25345807 | 0.85 | LMNA (0.47) | TSHRKMT2ALMNAALDH1A1RECQL | |
| SCHEMBL1246160 | 0.85 | LMNA (0.47) | TSHRKMT2ALMNAALDH1A1RECQL | |
| SCHEMBL17725713 | 0.84 | LTA4H (0.40) | TSHRKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL31638052 | 0.83 | TSHR (0.44) | TSHRKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL24614984 | 0.83 | MEN1 (0.42) | TSHRKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL31614399 | 0.83 | MEN1 (0.42) | TSHRKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL28766685 | 0.82 | MLYCD (0.32) | DUT | |
| SCHEMBL24614982 | 0.81 | MEN1 (0.58) | TSHRKMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| EP-4577211-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | Wake Forest University Health Sciences (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| WO-2025096956-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044748-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11279694-B2 | Alvocidib prodrugs and their use as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2018094275-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | TSHR 4694/4885KMT2A 4381/4885MEN1 2072/4885 |
| US-11279694-B2 | Alvocidib prodrugs and their use as protein kinase inhibitors | CDK1, CDK2, CDK3 | TSHR 2355/4885KMT2A 488/4885MEN1 2700/4885 |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | TSHR 4694/4885KMT2A 4381/4885MEN1 2072/4885 |
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CDK2, CDK3 | TSHR 2355/4885KMT2A 488/4885MEN1 2700/4885 |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | TSHR 4694/4885KMT2A 4381/4885MEN1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.